Skip to content

Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.

Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study of 6\12\2021 to20\4\2023

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05719181
Acronym
rhBMP-2
Enrollment
32
Registered
2023-02-08
Start date
2021-12-06
Completion date
2023-04-20
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Disease, Diabetes Mellitus, Hypertension

Brief summary

Effect of Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.

Detailed description

The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group. Secondary outcome association of the effect of other factors (ridge dimension, bone density) on dental implant stability.

Interventions

BIOLOGICALrhBMP-2

Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .

Sponsors

University of Baghdad
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Intervention model description

two groups; first group with protein , second group without (control)

Eligibility

Sex/Gender
ALL
Age
25 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients have good oral hygiene. * Systemic healthy individuals ,Age more than18 years. * Healed edentulous area for at least 6 months after tooth extraction (delayed implant protocol). * Patients have at least two missing teeth in the jaw (canine to 1st molar area) indicated for the dental implant.

Exclusion criteria

* Presence of systemic diseases preventing implantation. * Previous implantation or augmentation of the same region. * The need for additional bone augmentation procedures (such as maxillary sinus augmentation) * Partial or total edentulous ridge associated with a severe knife-edge ridge . * Acute infection or any pathological lesion a the implant site. * Allergy to one of the materials to be used during operation. * Pregnancy. * Radiation therapy, bisphosphonate drugs , Osteoradionecrosis.

Design outcomes

Primary

MeasureTime frameDescription
Effect of Recombinant Human Bone Morphogenetic The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group.At the time of surgery ,all measurment (primary stability) was taken which represented the base line data.The topical application of rhBMP-2 in the osteotomy site has an effect through improve secondary stability of the dental implant.

Countries

Iraq

Contacts

Primary ContactAbdullah Al Abbas, B.D.S
abdsin313@gmail.com07816357260
Backup ContactAbdullah Al Abbas, B.D.S
abdsin313@gmail.com0781635726

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026